These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 387223)

  • 21. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine.
    Sastry J; Kellie SJ
    Pediatr Hematol Oncol; 2005; 22(5):441-5. PubMed ID: 16020136
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I trial of intermittent high-dose dacarbazine.
    Buesa JM; Gracia M; Valle M; Estrada E; Hidalgo OF; Lacave AJ
    Cancer Treat Rep; 1984 Mar; 68(3):499-504. PubMed ID: 6704980
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of cis-dichlorodiammineplatinum(II) (NSC-119875) in combination with cyclophosphamide (NSC-26271) in the treatment of human malignancies.
    Piel IJ; Perlia CP
    Cancer Chemother Rep; 1975; 59(5):995-9. PubMed ID: 1106849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I clinical and pharmacological study of thymidine (NSC 21548) and cis-diamminedichloroplatinum(II) in patients with advanced cancer.
    Schilsky RL; O'Laughlin K; Ratain MJ
    Cancer Res; 1986 Aug; 46(8):4184-8. PubMed ID: 3731086
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The clinical toxicity of anticancer drugs and its prediction.
    Creaven PJ; Mihich E
    Semin Oncol; 1977 Jun; 4(2):147-63. PubMed ID: 406677
    [No Abstract]   [Full Text] [Related]  

  • 26. Tetany: a complication of cis-dichlorodiammineplatinum(II) therapy.
    Hayes FA; Green AA; Senzer N; Pratt CB
    Cancer Treat Rep; 1979 Apr; 63(4):547-8. PubMed ID: 445508
    [No Abstract]   [Full Text] [Related]  

  • 27. Phase I investigation of ametantrone.
    Loesch DM; Von Hoff DD; Kuhn J; Coltman CA; Tio F; Chaudhuri TK; Bender JF; Grillo-Lopez AJ
    Cancer Treat Rep; 1983 Nov; 67(11):987-91. PubMed ID: 6640557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Palliative therapy in cancer. 5. Side effects by anticancer drugs and their treatments].
    Urushizaki I
    Gan To Kagaku Ryoho; 1990 Sep; 17(9):1959-69. PubMed ID: 1697455
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cis-platinum (CDDP) plus etoposide (VP-16-213) and treatment of disseminated neuroblastoma.
    Helson L
    Anticancer Res; 1986; 6(6):1337-40. PubMed ID: 3813490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A review of cis-platinum ototoxicity.
    Moroso MJ; Blair RL
    J Otolaryngol; 1983 Dec; 12(6):365-9. PubMed ID: 6686617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. cis-Platinum in gynecologic cancer. III. Toxicity.
    Hall DJ; Diasio R; Goplerud DR
    Am J Obstet Gynecol; 1981 Oct; 141(3):309-12. PubMed ID: 7197123
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cis-dichlorodiammineplatinum in osteosarcoma. Osteosarcoma Cooperative Study Group report].
    Fukuma H; Beppu Y; Chuman H; Yagi T; Yamawaki S; Isu K; Funayama K; Tanuma M; Abe Y; Toriyama S
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 1):811-7. PubMed ID: 2653222
    [TBL] [Abstract][Full Text] [Related]  

  • 33. cis-Dichlorodiammineplatinum(II)-based chemotherapy as initial treatment of advanced head and neck cancer.
    Wittes R; Heller K; Randolph V; Howard J; Vallejo A; Farr H; Harrold C; Gerold F; Shah J; Spiro R; Strong E
    Cancer Treat Rep; 1979; 63(9-10):1533-8. PubMed ID: 498153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Qualitative and quantitative toxicity of sublethal doses of methyl-CCNU in BDF1 mice.
    Denine EP; Harrison SD; Peckham JC
    Cancer Treat Rep; 1977; 61(3):409-17. PubMed ID: 872140
    [No Abstract]   [Full Text] [Related]  

  • 35. Ototoxicity of cis-diamminedichloroplatinum.
    Vodvárka P; Foukalová J; Mrázek J; Philippová J
    Neoplasma; 1985; 32(2):229-38. PubMed ID: 4039797
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of cis-dichlorodiammineplatinum(II) in childhood osteosarcoma: Children's Cancer Study Group Report.
    Baum ES; Gaynon P; Greenberg L; Krivit W; Hammond D
    Cancer Treat Rep; 1979; 63(9-10):1621-7. PubMed ID: 291484
    [No Abstract]   [Full Text] [Related]  

  • 37. Phase II trial of cisplatin in small cell carcinoma of the lung.
    Levenson RM; Ihde DC; Huberman MS; Cohen MH; Bunn PA; Minna JD
    Cancer Treat Rep; 1981; 65(9-10):905-7. PubMed ID: 6268297
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Synopsis of the hydantoins].
    Gottwald W
    Fortschr Neurol Psychiatr Grenzgeb; 1969 Nov; 37(11):573-648. PubMed ID: 4901428
    [No Abstract]   [Full Text] [Related]  

  • 39. Cis-dichlorodiammineplatinum(II) in advanced bladder cancer.
    Yagoda A; Watson RC; Gonzalez-Vitale JC; Grabstald H; Whitmore WF
    Cancer Treat Rep; 1976 Jul; 60(7):917-23. PubMed ID: 1009522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II trial cisplatin, doxorubicin, and cyclophosphamide (CAP) in the treatment of urothelial transitional cell carcinoma.
    Campbell M; Baker LH; Opipari M; Al-Sarraf M
    Cancer Treat Rep; 1981; 65(9-10):897-9. PubMed ID: 7196800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.